• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Vaqta
    / MSD

    Active Ingredient

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    1 Vial x 25 U/0.5 ml

    not in the basket chart


    1 Vial x 50 U/ml

    not in the basket chart 66549 22179


    Active pre-exposure prophylaxis against disease caused by Hepatitis A virus in persons 2 years and older. Primary immunization should be given at least 2 weeks prior to expected exposure to HIV.
    See prescribing information for full details.


    Hypersensitivity to any component of the vaccine.

    Special Precautions

    Will not prevent hepatitis caused by infectious agents other than hepatitis A virus, bleeding disorders in people who are at risk of hemorrhage, acute infection or febrile illness, pregnancy and lactation.

    Side Effects

    No serious vaccine-related adverse experiences were observed during clinical trials.

    Drug interactions

    None reported.

    Merck Sharp & Dohme B.V., Haarlem, Holland